CONNORS, J.M.,
SAVAGE, K.J,
JURCZAK, W,
LECH-MARANDA, E.,
SMOLEWSKI, P,
WALEWSKI, J,
STRAUS, D.J.,
YOUNES, A.,
ANSELL, S.M.,
KIM, W.S.,
GALLAMINI, A.,
ALEKSEEV, S.,
ILLÉS, A.,
ROSTA, A.,
PICARDI, M.,
ZINZANI, P.L.,
OKI, Y.,
FELDMAN, T.,
BARTLETT, N.L.,
CHEN, R.,
RAMCHANDREN, R.,
CUNNINGHAM, D.,
RADFORD, J.,
JOSEPHSON, N.C.,
SONG, E.,
SACHS, J.,
JOLIN, H.A.,
HUEBNER, D.,
LIU, R.,
LIPATOV, O.N. (2018) modified progression-free
survival rates
in the A+AVD and ABVD groups were 82.1% (95% confidence interval
PROMZELEVA, M.,
VOLKOVA, T.,
SILUYKOV, O.,
TEREKHOVA, I.,
PROSHIN, A.,
MAZUR, A.,
TOLSTOY, P.,
IVANOV, S.,
KAMILOV, F. (2018)
solubility and dissolution
rate. Novel oral formulations of thiadiazole with β- and
hydroxypropyl